JP7148605B2 - 医学療法におけるセマグルチド - Google Patents

医学療法におけるセマグルチド Download PDF

Info

Publication number
JP7148605B2
JP7148605B2 JP2020517328A JP2020517328A JP7148605B2 JP 7148605 B2 JP7148605 B2 JP 7148605B2 JP 2020517328 A JP2020517328 A JP 2020517328A JP 2020517328 A JP2020517328 A JP 2020517328A JP 7148605 B2 JP7148605 B2 JP 7148605B2
Authority
JP
Japan
Prior art keywords
semaglutide
medicament
subject
administered
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020517328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536854A5 (enExample
JP2020536854A (ja
Inventor
カビッシュ、マリア
ハンセン、トーマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60083831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7148605(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2020536854A publication Critical patent/JP2020536854A/ja
Publication of JP2020536854A5 publication Critical patent/JP2020536854A5/ja
Priority to JP2022112446A priority Critical patent/JP7475398B2/ja
Application granted granted Critical
Publication of JP7148605B2 publication Critical patent/JP7148605B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2020517328A 2017-10-12 2018-10-10 医学療法におけるセマグルチド Active JP7148605B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022112446A JP7475398B2 (ja) 2017-10-12 2022-07-13 医学療法におけるセマグルチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17196254.1 2017-10-12
EP17196254 2017-10-12
PCT/EP2018/077654 WO2019072941A1 (en) 2017-10-12 2018-10-10 SEMAGLUTIDE IN MEDICAL THERAPY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022112446A Division JP7475398B2 (ja) 2017-10-12 2022-07-13 医学療法におけるセマグルチド

Publications (3)

Publication Number Publication Date
JP2020536854A JP2020536854A (ja) 2020-12-17
JP2020536854A5 JP2020536854A5 (enExample) 2021-07-29
JP7148605B2 true JP7148605B2 (ja) 2022-10-05

Family

ID=60083831

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020517328A Active JP7148605B2 (ja) 2017-10-12 2018-10-10 医学療法におけるセマグルチド
JP2022112446A Active JP7475398B2 (ja) 2017-10-12 2022-07-13 医学療法におけるセマグルチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022112446A Active JP7475398B2 (ja) 2017-10-12 2022-07-13 医学療法におけるセマグルチド

Country Status (18)

Country Link
US (5) US12029779B2 (enExample)
EP (1) EP3694538A1 (enExample)
JP (2) JP7148605B2 (enExample)
KR (1) KR20200069316A (enExample)
CN (4) CN120241968A (enExample)
AU (2) AU2018348929B2 (enExample)
BR (1) BR112020006246A2 (enExample)
CA (1) CA3078652A1 (enExample)
CL (1) CL2020000812A1 (enExample)
IL (3) IL322969A (enExample)
MA (1) MA50358A (enExample)
MX (3) MX2020003049A (enExample)
MY (1) MY204827A (enExample)
PH (1) PH12020550185A1 (enExample)
SG (1) SG11202002841PA (enExample)
TW (1) TWI842681B (enExample)
WO (1) WO2019072941A1 (enExample)
ZA (3) ZA202503388B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3078652A1 (en) * 2017-10-12 2019-04-18 Novo Nordisk A/S Semaglutide in medical therapy
US12605426B2 (en) 2020-02-14 2026-04-21 G2Gbio, Inc. Pharmaceutical comprising sustained-release microspheres including GLP-1 analogue or pharmaceutically acceptable salt thereof
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
WO2022212271A1 (en) * 2021-03-29 2022-10-06 Sanford Health Methods and compositions for treating lysosomal storage disorders
AU2023285400A1 (en) * 2022-06-08 2024-12-05 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
WO2024249659A2 (en) * 2023-05-30 2024-12-05 The Medical College Of Wisconsin, Inc. Methods for weight loss and/or reducing weight gain
US12597496B2 (en) * 2023-06-05 2026-04-07 Closed Loop Medicine Ltd. Dosing of incretin pathway drugs
US20260007869A1 (en) 2023-06-23 2026-01-08 Vaxess Technologies, Inc. Microneedle array patches (maps), systems, and methods for manufacturing and using same
US20260199436A1 (en) * 2025-01-16 2026-07-16 Novo Nordisk A/S Semaglutide in medical therapy including weight management

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015522573A (ja) 2012-07-01 2015-08-06 ノヴォ ノルディスク アー／エス 長時間作用型ｇｌｐ−１ペプチドの使用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
ES2298378T3 (es) 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
KR101243648B1 (ko) 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
RU2413530C9 (ru) 2004-11-12 2021-05-18 Ново Нордиск А/С Стабильные препараты инсулинотропных пептидов
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
RU2409349C2 (ru) 2006-04-14 2011-01-20 Маннкайнд Корпорейшн Фармацевтические композиции, содержащие глюкагонподобный пептид(glp-1)
DK2481410T3 (en) 2007-01-31 2016-10-24 Bial - Portela & Ca S A Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen
EP2121897A4 (en) 2007-03-20 2010-03-31 Nippon Kayaku Kk METHOD FOR MONITORING THE DRUG EFFECT ON DIABETES PATIENTS USING AN ASSAY FOR 1,5-ANHYDRO-D-GLUCITOL
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
HUE031900T2 (en) 2008-12-10 2017-08-28 Glaxosmithkline Llc Pharmaceutical compositions containing Albiglutide
WO2010092163A2 (en) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Antidiabetic medications
US20120329711A1 (en) 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
MX341025B (es) * 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
CN102203130B (zh) 2010-08-06 2014-06-25 贝达药业股份有限公司 Glp-1衍生物及其应用
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
RU2013133803A (ru) 2010-12-22 2015-01-27 Маркадиа Байотек, Инк. Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
US20140220134A1 (en) 2011-06-24 2014-08-07 Astrazeneca Pharamceuticals LP Method for treating diabetes with extended release formulation of glp-1 receptor agonists
SI2753312T1 (sl) 2011-09-08 2017-10-30 Mereo Biopharma 2 Limited Uporaba inhibitorja aromataze za zdravljenje hipogonadizma in sororodnih bolezni
EP2846823B1 (en) 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
RS58039B1 (sr) * 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
CN117106085A (zh) 2015-12-23 2023-11-24 美国安进公司 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
CA3078652A1 (en) 2017-10-12 2019-04-18 Novo Nordisk A/S Semaglutide in medical therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015522573A (ja) 2012-07-01 2015-08-06 ノヴォ ノルディスク アー／エス 長時間作用型ｇｌｐ−１ペプチドの使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ＮＣＴ０２４５３７１１，ＣｌｏｎｉｃａｌＴｒｉａｌｓ．ｇｏｖ ａｒｃｈｉｖｅ，２０１７年７月

Also Published As

Publication number Publication date
US12295988B2 (en) 2025-05-13
MX2025002188A (es) 2025-04-02
CN111212657A (zh) 2020-05-29
AU2018348929A1 (en) 2020-05-07
US20240316159A1 (en) 2024-09-26
IL273470A (en) 2020-05-31
JP2020536854A (ja) 2020-12-17
JP2022132414A (ja) 2022-09-08
AU2026206205A1 (en) 2026-08-06
MA50358A (fr) 2020-08-19
RU2020114960A (ru) 2021-10-28
SG11202002841PA (en) 2020-04-29
CN119838000A (zh) 2025-04-18
AU2018348929B2 (en) 2025-02-27
US20260232771A1 (en) 2026-08-13
MX2025002189A (es) 2025-04-02
ZA202503388B (en) 2025-09-25
BR112020006246A2 (pt) 2021-03-30
CN119950682A (zh) 2025-05-09
CN120241968A (zh) 2025-07-04
WO2019072941A1 (en) 2019-04-18
EP3694538A1 (en) 2020-08-19
RU2020114960A3 (enExample) 2022-02-11
IL322969A (en) 2025-10-01
TW201914611A (zh) 2019-04-16
ZA202503350B (en) 2025-09-25
US12029779B2 (en) 2024-07-09
US20250235511A1 (en) 2025-07-24
ZA202503387B (en) 2025-09-25
TWI842681B (zh) 2024-05-21
IL322968A (en) 2025-10-01
US20200237876A1 (en) 2020-07-30
PH12020550185A1 (en) 2021-03-01
US12551536B2 (en) 2026-02-17
US20240415935A1 (en) 2024-12-19
MY204827A (en) 2024-09-18
KR20200069316A (ko) 2020-06-16
CA3078652A1 (en) 2019-04-18
MX2020003049A (es) 2020-07-27
AU2025203535A1 (en) 2025-06-05
CL2020000812A1 (es) 2020-08-14
JP7475398B2 (ja) 2024-04-26

Similar Documents

Publication Publication Date Title
JP7475398B2 (ja) 医学療法におけるセマグルチド
Goldenberg et al. Semaglutide: review and place in therapy for adults with type 2 diabetes
CN103458919A (zh) 在2型糖尿病患者中预防低血糖症
Bain et al. Recent developments in GLP‐1RA therapy: a review of the latest evidence of efficacy and safety and differences within the class
US20240189394A1 (en) Methods of using and compositions containing dulaglutide
US20240100127A1 (en) Tirzepatide therapeutic methods
Provilus et al. Weight gain associated with antidiabetic medications
RU2800651C2 (ru) Семаглутид в лекарственной терапии
CN115397455A (zh) Glp-1给药方案
BR122025013280A2 (pt) Uso de semaglutida para fabricar uma solução injetável subcutânea para tratar diabetes tipo 2
BR122024015864A2 (pt) Uso de semaglutida para preparação de uma composição farmacêutica para controle de peso
BR122024015868A2 (pt) Uso de semaglutida para preparação de uma composição farmacêutica para tratamento e/ou prevenção de obesidade e/ou de sobrepeso
Tofé et al. Effectiveness, Safety and Therapeutic Adherence of Weekly Subcutaneous Semaglutide for Weight Management in Real Practice: An Observational Study
Harkin et al. Adjunct liraglutide use in people with type 1 diabetes in the St Vincent's Healthcare Group, Dublin: An Irish perspective.

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20200325

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20200501

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20200513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210618

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211026

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220314

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220713

C876 Explanation why request for accelerated appeal examination is justified

Free format text: JAPANESE INTERMEDIATE CODE: C876

Effective date: 20220713

C305 Report on accelerated appeal examination

Free format text: JAPANESE INTERMEDIATE CODE: C305

Effective date: 20220726

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220801

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220815

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220912

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220912

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220922

R150 Certificate of patent or registration of utility model

Ref document number: 7148605

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153